Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis update
暂无分享,去创建一个
[1] C. Wheeler,et al. Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial , 2006, The Lancet.
[2] S. Franceschi,et al. Re: A study of the impact of adding HPV types to cervical cancer screening and triage tests. , 2005, Journal of the National Cancer Institute.
[3] Cosette M Wheeler,et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.
[4] S. Franceschi,et al. Human Papillomavirus Genotype Distribution in Low-Grade Cervical Lesions: Comparison by Geographic Region and with Cervical Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.
[5] Xavier Castellsagué,et al. Against which human papillomavirus types shall we vaccinate and screen? the international perspective , 2004, International journal of cancer.
[6] S. Franceschi,et al. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis , 2003, British Journal of Cancer.
[7] T. Iftner,et al. Chapter 12: Human papillomavirus technologies. , 2003, Journal of the National Cancer Institute. Monographs.
[8] M. Plummer,et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis , 2003, British Journal of Cancer.
[9] C. Woodman,et al. Human papillomavirus type 18 and rapidly progressing cervical intraepithelial neoplasia , 2003, The Lancet.
[10] T. Iftner,et al. Human papillomavirus technologies , 2003 .
[11] J. Peto,et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.
[12] H. Bartsch,et al. International Agency for Research on Cancer. , 1969, WHO chronicle.